Novavax Inc (NVAX)
Health Care ยท Biological Products, (No Diagnostic Substances)
Novavax Inc (NVAX) is listed on Nasdaq, where its shares have traded since December 5, 1995. SentiSense covers Novavax Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). John C. Jacobs is its chief executive officer. The company reports 749 employees, and its corporate website is www.novavax.com.
About Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Latest reported results
Novavax, Inc. reported revenue of $68.3 million for Q3 FY2026, down 3.0% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 259 institutions reported holding NVAX, with 117.4 million shares worth $1.1 billion in aggregate. The largest reported holders were Vanguard, Shah Capital Management and BlackRock.
More on NVAX
- NVAX sentiment: whether news and social coverage of Novavax Inc leans bullish or bearish, and the stories driving it.
- NVAX ownership: all 259 reporting institutions, plus insider and congressional trades.
- NVAX financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Novavax Inc do?
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
What sector is NVAX in?
SentiSense classifies Novavax Inc in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does NVAX stock trade?
Novavax Inc (NVAX) is listed on Nasdaq, where its shares have traded since December 5, 1995.
Who is the CEO of Novavax Inc?
John C. Jacobs is the chief executive officer of Novavax Inc.